RB0 Stock Chart & Stats
€8.27
-€0.30(-3.50%)
At close: 4:00 PM EDT
€8.27
-€0.30(-3.50%)
Day’s Range― - ―
52-Week Range€4.73 - €13.60
Previous CloseN/A
Volume0.00
Average Volume (3M)231.00
Market Cap
€548.76M
Enterprise Value€537.25
Total Cash (Recent Filing)€150.49M
Total Debt (Recent Filing)€71.07M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Aug 06, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.60
Shares Outstanding65,310,360
10 Day Avg. Volume0
30 Day Avg. Volume231
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)7.23
Price to Sales (P/S)4.36
P/FCF Ratio-5.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€21.91Price Target Upside164.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-2.53
Revenue Forecast (FY)€200.22M
Bulls Say, Bears Say
Bulls Say
Pivotal Phase III Success And Surrogate LinkageA pivotal Phase III that met its primary endpoint and showed a >0.9 correlation between microdystrophin and functional measures materially de-risks development. This durable scientific link supports regulatory reliance on a surrogate, raising the probability of accelerated approval and long-term commercial viability if confirmed.
Validated Partner Collaboration And Milestone FundingA $100M milestone from AbbVie tied to dosing validates REGENXBIO's NAV platform and injects significant non-dilutive capital. Durable partner funding both extends runway and signals commercial confidence, while collaboration economics (milestones/royalties) scale revenue without sole commercialization risk.
Platform Licensing Business ModelA platform-based licensing model allows recurring, milestone-linked revenue and royalties from multiple partners. Over the medium term this diversifies income sources, leverages core IP across programs, and can fund R&D while spreading technical and commercial risk across partner portfolios.
Bears Say
Heavy Cash Burn And Negative Free Cash FlowSustained, large negative operating and free cash flows imply ongoing external financing needs. Over 2–6 months this raises dilution and execution risk if milestone timing slips; the company must secure partner payments or capital to fund pivotal programs and commercialization preparations without impairing strategy.
Elevated Leverage And Thin Equity CushionHigh leverage versus a very small equity base constrains financial flexibility and raises refinancing risk. If clinical or regulatory timelines extend, interest and principal obligations could force dilutive financings, asset monetization, or curtailed investment in commercialization, weakening strategic optionality.
Regulatory Uncertainty And Limited Mature Functional DataReliance on external controls and a small mature functional dataset leave approval pathways uncertain. If regulators demand randomized trials, timelines and costs could expand materially, delaying revenue and stressing capital resources; limited durability data also keeps long-term benefit and label scope unresolved.
RegenXBio News
RB0 FAQ
What was RegenXBio’s price range in the past 12 months?
RegenXBio lowest stock price was €4.73 and its highest was €13.60 in the past 12 months.
What is RegenXBio’s market cap?
RegenXBio’s market cap is €548.76M.
When is RegenXBio’s upcoming earnings report date?
RegenXBio’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were RegenXBio’s earnings last quarter?
RegenXBio released its earnings results on May 14, 2026. The company reported -€1.494 earnings per share for the quarter, missing the consensus estimate of -€1.161 by -€0.333.
Is RegenXBio overvalued?
According to Wall Street analysts RegenXBio’s price is currently Undervalued.
Does RegenXBio pay dividends?
RegenXBio does not currently pay dividends.
What is RegenXBio’s EPS estimate?
RegenXBio’s EPS estimate is 0.07.
How many shares outstanding does RegenXBio have?
RegenXBio has 65,310,360 shares outstanding.
What happened to RegenXBio’s price movement after its last earnings report?
RegenXBio reported an EPS of -€1.494 in its last earnings report, missing expectations of -€1.161. Following the earnings report the stock price went down -2.335%.
Which hedge fund is a major shareholder of RegenXBio?
Currently, no hedge funds are holding shares in DE:RB0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RegenXBio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€21.91 (164.98% Upside)
€21.91 (164.98% Upside)
Blogger Sentiment
Bullish
DE:RB0 Sentiment 71%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
6.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.36%
Trailing 12-Months
Company Description
RegenXBio
REGENXBIO Inc. is a biotechnology company operating in the clinical stage, dedicated to developing gene therapy candidates. These therapies are designed to introduce genes into cells, aiming either to rectify genetic deficiencies or to stimulate the body's own cells to produce therapeutic proteins or antibodies to combat diseases. Central to its therapeutic development is the proprietary NAV Technology Platform, an adeno-associated virus-based gene delivery system. The company's primary investigational asset, RGX-314, is currently in Phase III clinical trials for treating wet age-related macular degeneration. Its pipeline also includes RGX-121 and RGX-111, both in Phase I/II trials for mucopolysaccharidosis type II and type I, respectively; RGX-181, which is in preclinical development for late-infantile neuronal ceroid lipofuscinosis type II disease; RGX-202, undergoing Phase I/II evaluation for Duchenne muscular dystrophy; and RGX-381, at the preclinical stage for addressing the ocular manifestations of CLN2 disease. In addition to its internal programs, REGENXBIO Inc. licenses its NAV Technology Platform to other biotech and pharmaceutical enterprises. It also maintains a collaborative and licensing agreement with Neurimmune AG for the advancement of innovative gene therapies. Founded in 2008, REGENXBIO Inc. maintains its headquarters in Rockville, Maryland.
RB0 Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a notably positive clinical and programmatic update: RGX-202 met its pivotal primary endpoint with high biomarker expression, demonstrated an unusually strong correlation between microdystrophin and functional benefit (>0.9), and showed encouraging interim safety and functional signals with plans for potential accelerated approval in 2027. Key operational and regulatory risks were acknowledged — chiefly the limited number of mature 12‑month functional datapoints so far, reliance on external controls (and FDA concern about bias), and the possibility that the agency could request randomized trials which would materially delay approval. Remaining uncertainties on long‑term durability and the logistical burden of the prophylaxis regimen were also discussed. Overall the clinical readout and pipeline progress meaningfully outweigh near‑term risks, but regulatory process and more mature datasets remain critical next milestones.View all DE:RB0 earnings summariesRB0 Stock 12 Month Forecast
Average Price Target
€21.91
▲(164.98% Upside)
Technical Analysis
Solid Biosciences
―
Monopar Therapeutics Inc
―
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―